India launched a ₹13,000-crore initiative, including the BioPharma SHAKTI Mission and three chemical parks, to shift from generic drugs to high-value biologics and specialty chemicals. It targets the $300-billion biosimilars market, boosts R&D and regulation via CDSCO, reduces import dependence, and requires coordinated government action.
Copyright infringement not intended
Picture Courtesy: PIB
The Government announced a ₹13,000 crore investment for the BioPharma SHAKTI Mission and three chemical parks to transition India from a generics "Pharmacy of the World" to a global biopharmaceuticals and specialty chemicals leader, supporting the "Viksit Bharat" vision.
The BioPharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) mission, announced in the Union Budget 2026–27, is a comprehensive plan to build a robust ecosystem for biopharmaceutical development in India.
Key Objectives & Financials
Major Pillars of the Mission
Academic Infrastructure: Establishment of 3 new National Institutes of Pharmaceutical Education and Research (NIPERs). Upgrading 7 existing NIPERs to create a highly specialised workforce.
Clinical Research: Creation of a nationwide network of over 1,000 accredited clinical trial sites to accelerate drug development and improve credibility.
Regulatory Strengthening: Enhancing the capacity of the Central Drugs Standard Control Organisation (CDSCO). Introducing a dedicated scientific review cadre to align approval timelines with global standards.
Manufacturing Hubs: Proposed establishment of dedicated Biomanufacturing Parks with plug-and-play models to reduce import dependence.
This mission complements earlier initiatives such as the National Biopharma Mission (NBM) and the Bio-RIDE scheme.
An allocation of ₹3,300 crore is dedicated to developing three world-class chemical parks to address the infrastructure deficit in the chemical industry. These parks will feature:
The successful Dahej PCPIR (Petroleum, Chemicals and Petrochemicals Investment Region) in Gujarat, which has attracted massive investment, serves as a blueprint for these new parks.
Environmental Compliance: The chemical industry is pollution-intensive. Strict adherence to norms set by the MoEFCC and Central Pollution Control Board (CPCB) is crucial for sustainable growth.
Regulatory Bottlenecks: Despite planned reforms, India's drug approval process can be slow. Sustained efforts are needed to make the CDSCO more agile and efficient.
Skill Gap: The shift to biologics and specialty chemicals requires a highly skilled workforce. Academia, particularly NIPERs, must align curricula with industry needs.
Import Dependence: India remains heavily reliant on China for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), posing a major supply chain vulnerability.
The government is promoting a "Whole of Government Approach" for effective implementation, ensuring collaboration between central ministries, state governments, and the private sector.
The path forward requires a focus on:
This strategic investment secures India's economic future, reinforces its global healthcare role, and will transform it into an innovation-driven chemical and biopharmaceutical powerhouse.
Source: PIB
|
PRACTICE QUESTION Q. What is the primary objective of the "Biopharma SHAKTI" mission proposed in the Union Budget 2026-27? A. To promote traditional Ayurvedic medicine exports B. To develop India as a global biopharma manufacturing centre C. To subsidize chemical drug production D. To reduce the cost of generic medicines Answer: B Explanation: The Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) mission was proposed in the Union Budget 2026-27 with an outlay of ₹10,000 crore over five years. Its primary goal is to transform India from a leader in generic drugs into a global manufacturing and innovation hub for high-value biopharmaceuticals, specifically biologics and biosimilars. |
The BioPharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) mission is a ₹10,000 crore initiative by the Indian government. Its goal is to create a robust ecosystem for biopharmaceutical development, reducing import dependency and positioning India as a global innovator and manufacturer of high-value biologics.
India is shifting its focus because the future of medicine lies in biologics (complex drugs from living organisms), which are projected to form 40% of all medicines by 2035. This strategic shift is from a high-volume, low-value generics market to a high-value, innovation-led biopharmaceutical sector to capture a larger share of the global market.
The key challenges include ensuring stringent environmental compliance for the chemical industry, overcoming regulatory bottlenecks by reforming bodies like the CDSCO, bridging the skill gap for a high-tech workforce, and reducing the dependence on imported Active Pharmaceutical Ingredients (APIs), especially from China.
© 2026 iasgyan. All right reserved
